

# Katarina VarnÅs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/558980/publications.pdf>

Version: 2024-02-01

60  
papers

2,965  
citations

236612

25  
h-index

168136

53  
g-index

61  
all docs

61  
docs citations

61  
times ranked

4317  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of sevoflurane anaesthesia on radioligand binding to monoamine oxidase-B in vivo. British Journal of Anaesthesia, 2021, 126, 238-244.	1.5	7
2	Preclinical Comparison of the Blood-brain barrier Permeability of Osimertinib with Other EGFR TKIs. Clinical Cancer Research, 2021, 27, 189-201.	3.2	106
3	Brain exposure of the ATM inhibitor AZD1390 in humans—a positron emission tomography study. Neuro-Oncology, 2021, 23, 687-696.	0.6	35
4	[ <sup>11</sup> C]CHDI-626, a PET Tracer Candidate for Imaging Mutant Huntingtin Aggregates with Reduced Binding to AD Pathological Proteins. Journal of Medicinal Chemistry, 2021, 64, 12003-12021.	2.9	15
5	A positron emission tomography study of the serotonin 1B receptor effect of electroconvulsive therapy for severe major depressive episodes. Journal of Affective Disorders, 2021, 294, 645-651.	2.0	6
6	Serotonin 1B receptor density mapping of the human brainstem using positron emission tomography and autoradiography. Journal of Cerebral Blood Flow and Metabolism, 2021, , 0271678X2110491.	2.4	1
7	A PET study in healthy subjects of brain exposure of <sup>11</sup> C-labelled osimertinib—a drug intended for treatment of brain metastases in non-small cell lung cancer. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 799-807.	2.4	36
8	The pro-psychotic metabotropic glutamate receptor compounds fenobam and AZD9272 share binding sites with monoamine oxidase-B inhibitors in humans. Neuropharmacology, 2020, 162, 107809.	2.0	10
9	Altered striatal dopamine levels in Parkinson's disease VPS35 D620N mutant transgenic aged mice. Molecular Brain, 2020, 13, 164.	1.3	10
10	Autoradiographic mapping of synaptic vesicle glycoprotein 2A in non-human primate and human brain. Synapse, 2020, 74, e22157.	0.6	14
11	Synthesis, Biodistribution, and Radiation Dosimetry of a Novel mGluR5 Radioligand: <sup>18</sup> F-AZD9272. ACS Chemical Neuroscience, 2020, 11, 1048-1057.	1.7	3
12	In vitro phosphodiesterase 10A (PDE10A) binding in whole hemisphere human brain using the PET radioligand [ <sup>18</sup> F]MNI-659. Brain Research, 2019, 1711, 140-145.	1.1	6
13	Synthesis and preclinical evaluation of [ <sup>18</sup> F]FSL25.1188, a reversible PET radioligand for monoamine oxidase-B. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1624-1627.	1.0	15
14	PET imaging of [ <sup>11</sup> C]PBR28 in Parkinson's disease patients does not indicate increased binding to TSPO despite reduced dopamine transporter binding. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 367-375.	3.3	50
15	The metabotropic glutamate receptor 5 radioligand [ <sup>11</sup> C]AZD9272 identifies unique binding sites in primate brain. Neuropharmacology, 2018, 135, 455-463.	2.0	13
16	The 5-HT1B receptor - a potential target for antidepressant treatment. Psychopharmacology, 2018, 235, 1317-1334.	1.5	56
17	Discovery of a Novel Muscarinic Receptor PET Radioligand with Rapid Kinetics in the Monkey Brain. ACS Chemical Neuroscience, 2018, 9, 224-229.	1.7	6
18	The brain-penetrant clinical ATM inhibitor AZD1390 radiosensitizes and improves survival of preclinical brain tumor models. Science Advances, 2018, 4, eaat1719.	4.7	201

#	ARTICLE	IF	CITATIONS
19	PET microdosing of CNS drugs. <i>Clinical and Translational Imaging</i> , 2017, 5, 291-298.	1.1	1
20	GABAA receptor occupancy by subtype selective GABAA $\alpha$ 2,3 modulators: PET studies in humans. <i>Psychopharmacology</i> , 2017, 234, 707-716.	1.5	21
21	Associations between cognition and serotonin receptor 1B binding in patients with major depressive disorder – A pilot study. <i>Psychiatry Research - Neuroimaging</i> , 2017, 267, 15-21.	0.9	1
22	Longitudinal Small-Animal PET Imaging of the zQ175 Mouse Model of Huntington Disease Shows In Vivo Changes of Molecular Targets in the Striatum and Cerebral Cortex. <i>Journal of Nuclear Medicine</i> , 2017, 58, 617-622.	2.8	19
23	Integrated Strategy for Use of Positron Emission Tomography in Nonhuman Primates to Confirm Multitarget Occupancy of Novel Psychotropic Drugs: An Example with AZD3676. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2016, 358, 464-471.	1.3	4
24	Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. <i>Clinical Cancer Research</i> , 2016, 22, 5130-5140.	3.2	554
25	Neurokinin-3 Receptor Binding in Guinea Pig, Monkey, and Human Brain: In Vitro and in Vivo Imaging Using the Novel Radioligand, [ <sup>18</sup> F]Lu AF10628. <i>International Journal of Neuropsychopharmacology</i> , 2016, 19, pyw023.	1.0	1
26	Discovery and Preclinical Validation of [11C]AZ13153556, a Novel Probe for the Histamine Type 3 Receptor. <i>ACS Chemical Neuroscience</i> , 2016, 7, 177-184.	1.7	7
27	A PET study comparing receptor occupancy by five selective cannabinoid 1 receptor antagonists in non-human primates. <i>Neuropharmacology</i> , 2016, 101, 519-530.	2.0	12
28	Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions – extending the simplified reference tissue model. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 116-127.	1.1	1
29	Development of rapid multistep carbon-11 radiosynthesis of the myeloperoxidase inhibitor AZD3241 to assess brain exposure by PET microdosing. <i>Nuclear Medicine and Biology</i> , 2015, 42, 555-560.	0.3	21
30	Amphetamine Decreases $\alpha$ 2C-Adrenoceptor Binding of [11C]ORM-13070: A PET Study in the Primate Brain. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyu081-pyu081.	1.0	13
31	Large Variation in Brain Exposure of Reference CNS Drugs: a PET Study in Nonhuman Primates. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv036.	1.0	34
32	Effect of the myeloperoxidase inhibitor AZD3241 on microglia: a PET study in Parkinson's disease. <i>Brain</i> , 2015, 138, 2687-2700.	3.7	168
33	Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 8200-8215.	2.9	113
34	Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: A PET study. <i>Synapse</i> , 2014, 68, 89-97.	0.6	23
35	Evaluation of Two Automated Methods for PET Region of Interest Analysis. <i>Neuroinformatics</i> , 2014, 12, 551-562.	1.5	27
36	Antidepressant effects on serotonin 1A/1B receptors in the rat brain using a gene x environment model. <i>Neuroscience Letters</i> , 2014, 559, 163-168.	1.0	16

#	ARTICLE	IF	CITATIONS
37	Positron emission tomography imaging of 5-hydroxytryptamine <sub>1B</sub> receptors in Parkinson's disease. <i>Neurobiology of Aging</i> , 2014, 35, 867-875.	1.5	25
38	Modeling of PET data in CNS drug discovery and development. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013, 40, 267-279.	0.8	37
39	Radiolabeling of the cannabinoid receptor agonist AZD1940 with carbon-11 and PET microdosing in non-human primate. <i>Nuclear Medicine and Biology</i> , 2013, 40, 410-414.	0.3	14
40	Radiosynthesis and evaluation of new $\alpha_1$ -adrenoceptor antagonists as PET radioligands for brain imaging. <i>Nuclear Medicine and Biology</i> , 2013, 40, 747-754.	0.3	7
41	A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066 – Estimating occupancy in the absence of a reference region. <i>NeuroImage</i> , 2013, 82, 160-169.	2.1	40
42	Arterial Input Function Derived from Pairwise Correlations Between PET-image Voxels. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 1058-1065.	2.4	76
43	A PET study with [ <sup>11</sup> C]AZ10419369 to determine brain 5-HT <sub>1B</sub> receptor occupancy of zolmitriptan in healthy male volunteers. <i>Cephalalgia</i> , 2013, 33, 853-860.	1.8	12
44	Clinical Validation of <sup>18</sup> F-AZD4694, an Amyloid- $\beta$ -Specific PET Radioligand. <i>Journal of Nuclear Medicine</i> , 2012, 53, 415-424.	2.8	204
45	Quantitative Analysis of [ <sup>11</sup> C]AZ10419369 Binding to 5-HT <sub>1B</sub> Receptors in Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 113-123.	2.4	72
46	Dose-dependent binding of AZD3783 to brain 5-HT <sub>1B</sub> receptors in non-human primates and human subjects: a positron emission tomography study with [ <sup>11</sup> C]AZ10419369. <i>Psychopharmacology</i> , 2011, 213, 533-545.	1.5	29
47	Radiosynthesis of the candidate $\beta$ -amyloid radioligand [ <sup>11</sup> C]AZD2184: Positron emission tomography examination and metabolite analysis in cynomolgus monkeys. <i>Synapse</i> , 2010, 64, 733-741.	0.6	26
48	Grey and White Matter Proportional Relationships in the Cerebellar Vermis Altered in Schizophrenia. <i>Cerebellum</i> , 2009, 8, 52-60.	1.4	17
49	Synthesis and in vitro autoradiographic evaluation of a novel high-affinity radioiodinated ligand for imaging brain cannabinoid subtype-1 receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2009, 19, 6209-6212.	1.0	12
50	Local and covariate-modulated false discovery rates applied in neuroimaging. <i>NeuroImage</i> , 2009, 47, 213-219.	2.1	4
51	Investigating possible subtypes of schizophrenia patients and controls based on brain cortical thickness. <i>Psychiatry Research - Neuroimaging</i> , 2008, 164, 254-264.	0.9	8
52	[ <sup>11</sup> C]AZ10419369: A selective 5-HT <sub>1B</sub> receptor radioligand suitable for positron emission tomography (PET). Characterization in the primate brain. <i>NeuroImage</i> , 2008, 41, 1075-1085.	2.1	78
53	Brain-derived neurotrophic factor polymorphisms and frontal cortex morphology in schizophrenia. <i>Psychiatric Genetics</i> , 2008, 18, 177-183.	0.6	27
54	Cerebellar volumes in men with schizophrenia and alcohol dependence. <i>Psychiatry and Clinical Neurosciences</i> , 2007, 61, 326-329.	1.0	23

#	ARTICLE	IF	CITATIONS
55	Regional expression of 5-HT1B receptor mRNA in the human brain. <i>Synapse</i> , 2005, 56, 21-28.	0.6	45
56	Autoradiographic distribution of serotonin transporters and receptor subtypes in human brain. <i>Human Brain Mapping</i> , 2004, 22, 246-260.	1.9	278
57	Distribution of 5-HT7 receptors in the human brain: a preliminary autoradiographic study using [ <sup>125</sup> I]SB-269970. <i>Neuroscience Letters</i> , 2004, 367, 313-316.	1.0	111
58	Distribution of 5-HT4 receptors in the postmortem human brain – an autoradiographic study using [ <sup>125</sup> I]SB 207710. <i>European Neuropsychopharmacology</i> , 2003, 13, 228-234.	0.3	67
59	New halogenated [ <sup>11</sup> C]WAY analogues, [ <sup>11</sup> C]6FPWAY and [ <sup>11</sup> C]6BPWAY – Radiosynthesis and assessment as radioligands for the study of brain 5-HT1A receptors in living monkey. <i>Nuclear Medicine and Biology</i> , 2001, 28, 177-185.	0.3	28
60	Autoradiographic mapping of 5-HT1B and 5-HT1D receptors in the post mortem human brain using [ <sup>3</sup> H]GR 125743. <i>Brain Research</i> , 2001, 915, 47-57.	1.1	99